Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is focused on developing cannabinoid-based therapies for various diseases and has a positive outlook due to its high enrollment rate (over 70%) in its Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer's dementia, upcoming milestones in mid-2026 for both the CALMA trial completion and the release of its AI beta program, its favorable current valuation and projected significant upside in its NPV analysis, and its strong focus on Alzheimer's disease, which is a large and growing market with no known cure or effective treatments.

Bears say

IGC Pharma is an early-stage drug development company with minimal revenue and a high net loss, reporting positive interim results for its Alzheimer's disease drug candidate IGC-AD1. However, despite a potential market opportunity and a recent increase in its price target, there are still significant risks for investors, such as balance sheet and liquidity concerns, regulatory hurdles, and potential competition.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.